Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.
Zoetis Inc. (NYSE: ZTS) is described as the world’s leading animal health company, and the ZTS news feed on Stock Titan brings together company announcements, regulatory updates and product developments that shape its story. Zoetis focuses on medicines, vaccines, diagnostics and technologies for animals, serving veterinarians, pet owners and livestock producers in over 100 countries.
News items for Zoetis often highlight its research and development activities and regulatory milestones. Recent releases include Health Canada approval for Portela (relfovetmab injection) to alleviate pain associated with osteoarthritis in cats and European Commission marketing authorization for Lenivia (izenivetmab) to reduce osteoarthritis pain in dogs. These updates illustrate Zoetis’ emphasis on monoclonal antibody therapies and long-acting pain management solutions for companion animals.
Investors can also follow financial and capital markets news, such as announcements of convertible senior notes offerings, senior notes issuances and the use of proceeds for share repurchases and capped call transactions. The company regularly reports dividends declared by its board of directors and provides quarterly and annual financial results through press releases and Form 8-K filings.
Zoetis participates in major healthcare conferences and hosts webcasts, including innovation-focused events that discuss its pipeline across chronic kidney disease, oncology, cardiology, osteoarthritis pain and dermatology. These events, along with earnings calls and conference presentations, are frequently covered in the news stream.
By monitoring the ZTS news page, readers can review product approvals, R&D updates, capital allocation decisions, credit facility arrangements and governance developments reported by Zoetis. This page can be revisited to see how new therapies, financial actions and strategic communications are disclosed over time.
Zoetis (NYSE: ZTS) announced an agreement to acquire Jurox, an animal health company known for its veterinary medicines for companion animals and livestock. This acquisition will enhance Zoetis' global expansion efforts, particularly in Australia, its fifth-largest market with $207 million in revenue in 2020. Jurox brings a valuable product portfolio, including Alfaxan®, and over 150 products aimed at animal health. The transaction, awaiting regulatory approval, is expected to close in the first half of 2022.
Zoetis is donating over 11,000 doses of its experimental COVID-19 vaccine to protect more than 100 mammalian species in nearly 70 zoos across 27 states. Authorized for use by the USDA, the vaccine aims to combat COVID-19 risks in at-risk animals, such as tigers and gorillas. The first vaccinations began at Oakland Zoo on June 30, 2021. The vaccine utilizes a unique formulation for animals, developed from Zoetis' extensive experience with other coronaviruses. This initiative reflects Zoetis' commitment to animal health and sustainability, as they monitor emerging infectious diseases.
Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on Aug. 5, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and answer questions from analysts. Investors can access the live webcast on the Zoetis investor site. The company, a leader in animal health, achieved $6.7 billion in revenue in 2020 and operates in over 100 countries, focusing on medicines, vaccines, and services for animal care.
Zoetis' A.L.P.H.A. initiative has significantly improved livestock health in Sub-Saharan Africa by administering 1.7 billion doses of vaccines and medicines, alongside over 650,000 diagnostic tests. Established in 2017 with a $14 million grant from the Gates Foundation, the program has trained over 13,200 individuals and established 10 serology labs. Zoetis submitted 85 veterinary products for approval and delivered 35 to the market, enhancing access to animal health services. The initiative aims to promote sustainable livestock practices, improve farmers' livelihoods, and contribute to economic development amidst challenges like COVID-19.
Summary not available.
Zoetis (NYSE:ZTS) will participate in the William Blair 41st Annual Growth Stock Conference on June 2, 2021. Glenn David, Executive Vice President and CFO, is set to present at 12:20 p.m. ET. Investors can access a live audio webcast of the presentation through the Zoetis investor relations website, with a replay available post-event. Zoetis, recognized as the leader in animal health, generated $6.7 billion in revenue in 2020 and employs approximately 11,300 staff worldwide, committed to advancing animal care.
Zoetis (NYSE:ZTS) will take part in the Stifel 2021 Virtual Jaws & Paws Conference on June 3, 2021. CEO Kristin Peck is scheduled to present at 2:00 p.m. ET and answer questions from analysts. Investors can access a live audio webcast of the presentation at investor.zoetis.com/events-presentations, with a replay available post-event. Zoetis, a leader in animal health, generated $6.7 billion in revenue in 2020 and employs approximately 11,300 people, committed to advancing animal care worldwide.
Zoetis (NYSE:ZTS) announced the results of its 2021 Annual Meeting of Shareholders and declared a quarterly dividend of $0.25 per share, payable on Sept. 1, 2021. CEO Kristin Peck highlighted a 9% operational revenue growth and 10% adjusted net income growth in 2020, aided by strong cash flow. The company elected new directors and approved compensation packages for executives. Zoetis aims to maintain its growth trajectory with a focus on innovations in pet care, diagnostics, and international markets.
Zoetis (NYSE:ZTS) announced leadership changes aimed at enhancing its growth strategy. Effective June 1, 2021, Glenn David transitions from CFO to Executive Vice President and Group President, focusing on international operations and growth areas like aquaculture and pet insurance. Wetteny Joseph joins as CFO, bringing extensive financial expertise from Catalent. Both executives are expected to drive innovation and expand market presence, particularly in crucial regions like China and Brazil. These changes reflect Zoetis' commitment to sustained growth and maximizing shareholder value.
Zoetis reported strong Q1 2021 results with $1.9 billion in revenue, a 22% increase year-over-year. Net income rose 32% to $559 million, or $1.17 per diluted share. Adjusted net income was $603 million, up 33%. The company raised its full-year revenue guidance to $7.500-$7.625 billion, citing robust operational growth across its product segments, particularly in companion animal products, and successful sales in international markets. New product approvals and a recovering veterinary sector contributed to positive momentum. CEO Kristin Peck emphasized the company's diverse portfolio and commitment to innovation.